Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension - Hoeper, Marius M.; Badesch, David B.; Ghofrani, H. Ardeschir; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; McLaughlin, Vallerie V.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron B.; Grünig, Ekkehard; Kopeć, Grzegorz; Meyer, Gisela; et al. (The New England journal of medicine, 2023)
Keywords: Adult; Apoptosis; Blood pressure; Body weight; Brain natriuretic peptide; Cardiology; Cardiology General; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Cardiovascular Agents - pharmacology; Cardiovascular Agents - therapeutic use; Clinical Medicine; Clinical Medicine General; Clinical trials; Cognitive ability; Committees; Critical Care; Critical Care General; Double-Blind Method; Emotions; Exercise Tolerance - drug effects; Functional morphology; Fusion protein; Hemodynamics; Hemoglobin; Humans; Hypertension; Hypertension, Pulmonary - drug therapy; Injections, Subcutaneous; International organizations; Life Sciences; Ligands; Morbidity; Outpatient-Based Clinical Medicine; Patients; Placebos; Pulmonary; Pulmonary Arterial Hypertension - diagnosis; Pulmonary Arterial Hypertension - drug therapy; Pulmonary arteries; Pulmonary Hypertension; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacology; Recombinant Fusion Proteins - therapeutic use; Respiratory System Agents - administration & dosage; Respiratory System Agents - adverse effects; Respiratory System Agents - pharmacology; Respiratory System Agents - therapeutic use; Signal transduction; Thrombocytopenia; Treatment Outcome; Vascular Resistance - drug effects; Veins & arteries; Walk Test; new treatment; Pulmonary Arterial Hypertension